This Proleukin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historic period can be attributed to the increased availability of Proleukin in global markets, expanded insurance coverage for immunotherapy drugs, greater physician acceptance of IL-2-based treatments, a surge in global cancer diagnostics, and rising healthcare expenditure in oncology.
The growth projected for the forecast period is driven by the rising demand for effective treatments for advanced cancer stages, an increasing need for advanced treatments for rare cancers, growing clinical evidence supporting Proleukin’s efficacy, greater support from healthcare organizations for immuno-oncology treatments, and a rising number of cancer patients. Key trends during the forecast period include advancements in biologic therapies, the development of combination therapies using Proleukin, technological innovations, strategic collaborations and partnerships, and progress in cancer vaccine development.
The growing cancer disease is expected to drive the growth of the proleukin market going forward. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and metastasize to other body parts. The increasing prevalence of cancer is driven by an aging population, improved detection methods, lifestyle changes, environmental exposures, and better survival rates. Proleukin, a high-dose interleukin-2 therapy, stimulates the immune system to target and destroy cancer cells, offering potential treatment for advanced cancers such as metastatic melanoma and renal cell carcinoma. For instance, in February 2024, the World Health Organization reported an estimated 20 million new cancer cases in 2022, with projections indicating over 35 million new cases by 2050. Therefore, the growing cancer disease is driving the growth of the Proleukin market.
The increasing research and development activities are expected to drive the growth of the proleukin market going forward. Research and development (R&D) involves scientific efforts to create innovative products, improve existing ones, and develop new solutions. R&D activities are rising due to the demand for technological advancements and the need to address emerging global challenges. Increased R&D in the pharmaceutical industry contributes to enhancing Proleukin's efficacy, exploring new cancer indications, improving delivery methods, and reducing side effects, which expands its clinical use. For example, in July 2024, the Department of Health and Social Care reported that the UK spent $11.3 billion on pharmaceutical R&D in 2022. Therefore, the increasing research and development activities are driving the growth of the Proleukin market.
In May 2023, Iovance Biotherapeutics, a US-based biotechnology company focused on T-cell-based cancer immunotherapies, acquired Proleukin (aldesleukin) from Clinigen Limited for an undisclosed amount. This acquisition allows Iovance to enhance its T-cell-based cancer immunotherapy platform by integrating Proleukin, a key immunotherapy agent. By incorporating Proleukin into its tumor-infiltrating lymphocyte (TIL) therapies, Iovance aims to improve the effectiveness of these therapies and further advance its pipeline of innovative cancer treatments. This acquisition strengthens Iovance's position in the competitive oncology market. Clinigen Group, a UK-based company, was the previous provider of Proleukin (aldesleukin).
Key player operating in the proleukin market is Novartis Pharmaceuticals Corporation.
North America was the largest region in the proleukin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proleukin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the proleukin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Proleukin is the brand name for aldesleukin, a recombinant form of interleukin-2 (IL-2), a naturally occurring protein in the body. As a biologic therapy, Proleukin is primarily used in oncology and immunotherapy. It works by stimulating the growth and activity of specific white blood cells (lymphocytes), boosting the immune system's ability to identify and target cancer cells.
The main formulations of proleukin include injection, powder, and others. Proleukin injection is a liquid form of aldesleukin, a recombinant interleukin-2, used for immune system modulation. It is indicated for various clinical conditions, including metastatic renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and other therapeutic areas in oncology, immunology, and beyond. Proleukin is distributed through both online and offline channels and is used in hospitals and pharmacies for both adult and pediatric patients.
The proleukin market research report is one of a series of new reports that provides proleukin market statistics, including proleukin industry global market size, regional shares, competitors with a proleukin market share, detailed proleukin market segments, market trends and opportunities, and any further data you may need to thrive in the proleukin industry. This proleukin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The proleukin market consists of sales of cancer vaccines, biosimilars, immune checkpoint inhibitors and adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historic period can be attributed to the increased availability of Proleukin in global markets, expanded insurance coverage for immunotherapy drugs, greater physician acceptance of IL-2-based treatments, a surge in global cancer diagnostics, and rising healthcare expenditure in oncology.
The growth projected for the forecast period is driven by the rising demand for effective treatments for advanced cancer stages, an increasing need for advanced treatments for rare cancers, growing clinical evidence supporting Proleukin’s efficacy, greater support from healthcare organizations for immuno-oncology treatments, and a rising number of cancer patients. Key trends during the forecast period include advancements in biologic therapies, the development of combination therapies using Proleukin, technological innovations, strategic collaborations and partnerships, and progress in cancer vaccine development.
The growing cancer disease is expected to drive the growth of the proleukin market going forward. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and metastasize to other body parts. The increasing prevalence of cancer is driven by an aging population, improved detection methods, lifestyle changes, environmental exposures, and better survival rates. Proleukin, a high-dose interleukin-2 therapy, stimulates the immune system to target and destroy cancer cells, offering potential treatment for advanced cancers such as metastatic melanoma and renal cell carcinoma. For instance, in February 2024, the World Health Organization reported an estimated 20 million new cancer cases in 2022, with projections indicating over 35 million new cases by 2050. Therefore, the growing cancer disease is driving the growth of the Proleukin market.
The increasing research and development activities are expected to drive the growth of the proleukin market going forward. Research and development (R&D) involves scientific efforts to create innovative products, improve existing ones, and develop new solutions. R&D activities are rising due to the demand for technological advancements and the need to address emerging global challenges. Increased R&D in the pharmaceutical industry contributes to enhancing Proleukin's efficacy, exploring new cancer indications, improving delivery methods, and reducing side effects, which expands its clinical use. For example, in July 2024, the Department of Health and Social Care reported that the UK spent $11.3 billion on pharmaceutical R&D in 2022. Therefore, the increasing research and development activities are driving the growth of the Proleukin market.
In May 2023, Iovance Biotherapeutics, a US-based biotechnology company focused on T-cell-based cancer immunotherapies, acquired Proleukin (aldesleukin) from Clinigen Limited for an undisclosed amount. This acquisition allows Iovance to enhance its T-cell-based cancer immunotherapy platform by integrating Proleukin, a key immunotherapy agent. By incorporating Proleukin into its tumor-infiltrating lymphocyte (TIL) therapies, Iovance aims to improve the effectiveness of these therapies and further advance its pipeline of innovative cancer treatments. This acquisition strengthens Iovance's position in the competitive oncology market. Clinigen Group, a UK-based company, was the previous provider of Proleukin (aldesleukin).
Key player operating in the proleukin market is Novartis Pharmaceuticals Corporation.
North America was the largest region in the proleukin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proleukin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the proleukin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Proleukin is the brand name for aldesleukin, a recombinant form of interleukin-2 (IL-2), a naturally occurring protein in the body. As a biologic therapy, Proleukin is primarily used in oncology and immunotherapy. It works by stimulating the growth and activity of specific white blood cells (lymphocytes), boosting the immune system's ability to identify and target cancer cells.
The main formulations of proleukin include injection, powder, and others. Proleukin injection is a liquid form of aldesleukin, a recombinant interleukin-2, used for immune system modulation. It is indicated for various clinical conditions, including metastatic renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and other therapeutic areas in oncology, immunology, and beyond. Proleukin is distributed through both online and offline channels and is used in hospitals and pharmacies for both adult and pediatric patients.
The proleukin market research report is one of a series of new reports that provides proleukin market statistics, including proleukin industry global market size, regional shares, competitors with a proleukin market share, detailed proleukin market segments, market trends and opportunities, and any further data you may need to thrive in the proleukin industry. This proleukin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The proleukin market consists of sales of cancer vaccines, biosimilars, immune checkpoint inhibitors and adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Proleukin Market Characteristics4. Proleukin Market Trends and Strategies5. Proleukin Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Proleukin Market Pricing Analysis & Forecasts30. Global Proleukin Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Proleukin Market32. Recent Developments in the Proleukin Market
3. Proleukin Market Biologic Drug Characteristics
6. Global Proleukin Growth Analysis and Strategic Analysis Framework
8. Proleukin Market Segmentation
9. Global Proleukin Market Epidemiology of Clinical Indications
10. Proleukin Market Regional and Country Analysis
11. Asia-Pacific Proleukin Market
12. China Proleukin Market
13. India Proleukin Market
14. Japan Proleukin Market
15. Australia Proleukin Market
16. South Korea Proleukin Market
17. Western Europe Proleukin Market
18. UK Proleukin Market
19. Germany Proleukin Market
20. France Proleukin Market
21. Eastern Europe Proleukin Market
22. North America Proleukin Market
23. USA Proleukin Market
24. Canada Proleukin Market
25. South America Proleukin Market
26. Middle East Proleukin Market
27. Africa Proleukin Market
28. Proleukin Market Competitive Landscape and Company Profiles
29. Global Proleukin Market Pipeline Analysis
33. Proleukin Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Proleukin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on proleukin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for proleukin? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proleukin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Injection; Powder; Other Types2) by Therapeutic Area: Oncology; Immunology; Other Therapeutic Areas
3) by Clinical Indication: Metastatic Renal Cell Carcinoma (RCC); Non-Small Cell Lung Cancer (NSCLC); Other Indications
4) by Application: Hospital; Pharmacy
5) by End-User: Adults; Pediatrics
Key Companies Mentioned: Novartis Pharmaceuticals Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novartis Pharmaceuticals Corporation
